Notably, drugs that target EGFR, such as gefitinib, erlotinib, and osimertinib, were also highly effective, suggesting a potential role for EGFR‐targeted drugs in HER2‐positive patients.[23] Additionally, the results highlight the intersample heterogeneity between different HER2‐positive breast cancer tissues. This evidence concerns the gene EGFR and breast carcinoma.